New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment

Revista da Sociedade Brasileira de Medicina Tropical

Coelho, Eduardo Antonio Ferraz¹  Tavares, Carlos Alberto Pereira¹  Coelho, Cecília Steinberg Perilo¹  Chávez-Fumagalli, Miguel Angel¹  Bioprospection Ltda, Belo Horizonte, Brazil¹  Universidad Autónoma de Madrid, Spain¹  Soto, Manuel¹  Castilho, Rachel Oliveira¹  Mendonça, Débora Vasconcelos Costa¹  Universidade Federal de Minas Gerais, Belo Horizonte, Brazil¹  Cardoso, Valbert Nascimento¹  Faraco, André Augusto Gomes¹  Fernandes, Simone Odília Antunes¹  Ribeiro, Tatiana Gomes¹ 

关键词: Amphotericin B;    Leishmaniasis;    Nanoparticles;    Toxicity;    Treatment;    Lipid-based formulations;   

DOI  :  10.1590/0037-8682-0138-2015

学科分类：农业科学（综合）

来源: Sociedade Brasileira de Medicina Tropical

【 摘 要 】

Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease of medical, social and economic importance in endemic areas. No vaccine is yet available for human use, and chemotherapy presents several problems. Pentavalent antimonials have been the drugs of choice to treat the disease for more than six decades; however, they exhibit high toxicity and are not indicated for children, for pregnant or breastfeeding women or for chronically ill patients. Amphotericin B (AmpB) is a second-line drug, and although it has been increasingly used to treat visceral leishmaniasis (VL), its clinical use has been hampered due to its high toxicity. This review focuses on the development and in vivo usage of new delivery systems for AmpB that aim to decrease its toxicity without altering its therapeutic efficacy. These new formulations, when adjusted with regard to their production costs, may be considered new drug delivery systems that promise to improve the treatment of leishmaniasis, by reducing the side effects and the number of doses while permitting a satisfactory cost-benefit ratio.Key words: Amphotericin B; Leishmaniasis; Nanoparticles; Toxicity; Treatment; Lipid-based formulations

【 授权许可】

Unknown